Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LifeSpan Vision Ventures is a Connecticut-based venture capital firm founded by Andrew Worden. Established with the mission to enable humans to live healthy, strong, and vibrant lives beyond 120 years, the firm focuses on investing in companies that develop therapeutics aimed at longevity and aging reversal. The firm operates from its headquarters in Norwalk, Connecticut, with additional teams located in San Francisco and London.
LifeSpan Vision Ventures has a portfolio of 19 companies, showcasing its commitment to the longevity and biotechnology sectors. The firm leverages its deep understanding of science and technology to accelerate development timelines through collaborations with academics, professionals, and institutions. This approach not only enhances the potential for successful outcomes but also fosters innovation in healthspan-related projects.
Notable milestones include participation in significant industry events such as the BIO International Convention, which highlights the firm’s active engagement with the broader biotech ecosystem. LifeSpan Vision Ventures has also established connections with leading research institutions, further solidifying its position in the longevity investment space.
LifeSpan Vision Ventures invests in early to mid-stage companies within the longevity and biotechnology sectors, specifically targeting therapeutics aimed at longevity and aging reversal. The firm participates in founding, seed, angel, and investment rounds, demonstrating flexibility in its investment approach. Check sizes typically range from smaller pre-seed and seed investments to larger Series A follow-ons.
The firm’s investment thesis emphasizes diagnostics and therapeutics focused on key scientific areas such as telomere restoration, DNA damage repair, senolytics, mRNA therapies, and regenerative medicine. LifeSpan Vision Ventures seeks to partner with founders who are innovating in these domains, particularly those developing solutions that address the biological aspects of aging.
Geographically, the firm focuses on the United States, aligning its investment strategy with the growing demand for advancements in healthspan extension. LifeSpan Vision Ventures values collaboration and aims to leverage its scientific expertise to accelerate the development of portfolio companies, ultimately contributing to the mission of extending healthy lifespans.
LifeSpan Vision Ventures has a diverse portfolio of 19 companies, each contributing to the firm's mission of enhancing longevity and healthspan. Notable portfolio companies include:
This portfolio reflects LifeSpan Vision Ventures' commitment to investing in innovative solutions that address the challenges of aging and promote longevity.
Andrew Worden — Founder and Managing Partner. Andrew has a background as a serial entrepreneur and investor, previously serving as General Partner at Barron. He founded GameChange Solar and Soltas Energy, successfully building and selling ten solar plants by 2014. Andrew has also funded a longevity research initiative at Harvard's John A. Paulson School of Engineering and Applied Sciences, demonstrating his commitment to advancing longevity science.
Harry Robb — Principal. Harry brings experience from his previous role at Eisai, a major Japanese pharmaceutical company, where he sourced and evaluated life science therapeutics, techbio, and AI investment opportunities. His expertise in regenerative medicine and healthy aging enhances the firm's investment strategy.
Jordan B. Burton, Ph.D — Associate. Jordan holds a Ph.D. and contributes to the firm's scientific diligence and investment analysis. His academic background and research experience support LifeSpan Vision Ventures' focus on scientifically rigorous investments in the longevity sector.
To pitch LifeSpan Vision Ventures, founders should utilize the contact form available on the firm's website. It is essential to include a comprehensive pitch deck that outlines the business model, scientific foundation, and market opportunity. The firm prefers detailed presentations that clearly articulate the innovation and its potential impact on longevity.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory. The firm encourages direct outreach from founders who align with its investment thesis.
In September 2025, LifeSpan Vision Ventures signed a landmark deal with Eli Lilly for its portfolio company Remedium Bio, validating the firm's investment thesis and showcasing the potential of its portfolio companies. This partnership highlights the firm's commitment to advancing innovations in longevity therapeutics.
In October 2025, Algen Biotechnologies entered into a multi-target research collaboration with AstraZeneca, further demonstrating the commercial viability of LifeSpan Vision Ventures' investments. This collaboration is expected to enhance the development of precision medicines aimed at extending healthspan.
As of early 2026, LifeSpan Vision Ventures has made a total of 19 investments, reflecting a significant increase from 7 deals in 2023. This growth indicates a successful scaling of the firm's investment strategy and an active engagement in the longevity and biotechnology sectors.
What investment criteria does LifeSpan Vision Ventures prioritize?
LifeSpan Vision Ventures focuses on early to mid-stage companies developing therapeutics and diagnostics in the longevity and biotechnology sectors. Key areas of interest include telomere restoration, DNA damage repair, senolytics, mRNA therapies, and regenerative medicine.
How can founders pitch to LifeSpan Vision Ventures?
Founders can pitch their ideas through the contact form available on the LifeSpan Vision Ventures website. It is advisable to include a detailed overview of the business model, market potential, and scientific basis for the proposed solution.
What makes LifeSpan Vision Ventures different from other VC firms?
The firm’s unique focus on longevity and aging therapeutics sets it apart from general biotech funds. LifeSpan Vision Ventures combines deep scientific expertise with a collaborative approach to accelerate the development of its portfolio companies.
What is the geographic scope of LifeSpan Vision Ventures' investments?
LifeSpan Vision Ventures primarily invests in companies based in the United States, aligning its strategy with the growing demand for advancements in healthspan extension.
What type of post-investment involvement can founders expect?
LifeSpan Vision Ventures actively engages with its portfolio companies, leveraging its network of academics and professionals to facilitate collaborations that enhance development timelines and foster innovation.
What is the typical check size for investments?
The firm typically writes smaller checks at the pre-seed and seed stages, with the potential to participate in larger Series A follow-ons as companies progress.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.